Background
In the risk assessment of PCDDs, PCDFs, and dioxin-like (DL) PCBs,
regulatory authorities support the use of the toxic equivalency factor
(TEF)-scheme derived from a heterogeneous data set of the relative effect
potency (REPs) estimates.
Objectives
We sought to determine REPs for dioxin-like compounds (DLCs) using
expression of cytochrome P450 (CYP) 1A1
and 1B1 mRNA in human peripheral blood mononuclear cells
representing two different pathways.
Methods
We used a sex and age adjusted regression-based approach comparing
the strength of association between each DLC and the cytochrome P450
(CYP) 1A1 and 1B1
mRNA expression in 320 adults residing in an organochlorine-polluted area of
eastern Slovakia.
Results
We calculated REPs based on CYP1A1 expression for 4
PCDDs, 8 PCDFs, and 1 PCB congener, and based on CYP1B1
expression for 5 PCDFs and 11 PCB congeners. REPs from
CYP1A1 correlated with REPs previously derived from
thyroid volume (ρ = 0.85; p
< 0.001) and serum FT4 (ρ =
0.77; p = 0.009). The 13 log REPs from
CYP1A1 correlated with log WHO-TEFs (r
= 0.63; p = 0.015) and 11 log PCB REPs with
PCB consensus toxicity factors (CTFs) for compounds with WHO-TEFs
(r = 0.80; p = 0.003).
The complete set of derived 56 log REPs correlated with the log CTFs
(r = 0.77; p = 0.001)
and log WHO-TEFs (r = 0.81; p <
0.001).
Conclusions
REPs calculated from thyroid and cytochrome P450 endpoints
realistically reflect human exposure scenarios because they are based on
human chronic and low-dose exposures. While the CYP 1A1
seems more suitable for toxicity evaluation of PCDD/Fs, the CYP
1B1 is more apt for PCDFs and PCBs and reflects different
pathways.